Media

Journal Club: Discussing Quality of Life in Patients with Metastatic Prostate Cancer Following Treatment with Cabazitaxel Versus Abiraterone or Enzalutamide - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis, MD, PhD, and Zachary Klaassen, MD, MSc, discuss the recently published data (Lancet Oncology) from the CARD trial "Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide." Previously reported from the CARD Study in the NEJM cabazitaxel significantly improved radiographic progression-free survival and o...

Significantly Longer Duration of Overall Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - PROfound Study Journal Club - Zachary Klaassen and Christopher Wallis

Details
In this Journal Club, Zachary Klaassen and Christopher Wallis present on the recently published New England Journal of Medicine article Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer, data from the Phase 3 PROfound study. The primary outcome of the study was radiographic progression-free survival in cohort A, which was focused on BRCA1, BRCA2, and ATM mutant patients whi...

Global Society of Rare Genitourinary Tumors (GSRGT) - Andrea Necchi & Philippe Spiess

Details
Andrea Necchi, MD, and Philippe Spiess, MD, MS, FRCS(C), FACS, join Alicia Morgans, MD, MPH, to discuss the new international effort to develop a Global Society of Rare Genitourinary (GU) Cancers. The Global Society of Rare Genitourinary Tumors (GSRGT) will have both an educational and research mission to promote evidence-based diagnostic and treatment standards across the world through conference...

How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black

Details
Co-chair of the Bacillus Calmette Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer session during the 2020 Virtual Bladder Cancer Advocacy Network Think Tank (BCANTT) meeting, Peter Black, MD joins Ashish Kamat, MD, MBBS providing a succinct overview of this session highlighting the clinical and the translational panel which addresses defining treatment failure after BCG treatment for...

Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar

Details
The identification of predictive biomarkers for immunotherapy response is an area of intense research interest. In this conversation with Alicia Morgans, MD, MPH, Srikala Sridhar MD, MSc, FRCPC highlights her presentation from the European Society for Medical Oncology (ESMO) 2020 virtual meeting. At this meeting, Dr. Sridhar presented an assessment of potential biomarkers for response within the J...

High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi

Details
Bacillus Calmette-Guerin (BCG) has been the standard of care for patients with non-muscle invasive bladder cancer for decades. However, within five years of the first instillation of BCG therapy, about 50% of tumors recur, and 20% of tumors will progress. To overcome BCG resistance, we need to understand the mechanisms of a BCG therapeutic effect and identify molecular correlates that can predict...

Prostate Cancer Patient Journey - Ken Ma

Details
Ken Ma, diagnosed with prostate cancer in late 2010 shares his treatment journey along with his disease progression over the last ten years. He shares his decision to follow an aggressive and proactive approach to his treatment regimen, what approaches he saw success in, and what approaches failed him. Further in his disease progression, Mr. Ma was found to have a pathogenic mutation. Mr. Ma share...

Outcomes Related to Cancer Treatments in Patients with COVID-19 from the CCC19 Registry Analysis- Ali Khaki, Jeremy Warner & Petros Grivas

Details
The COVID-19 and Cancer Consortium (CCC19) is a consortium of over 120 cancer centers and organizations coming together to collect data about patients with cancer who have been diagnosed with COVID-19. Ali Khaki, MD, Jeremy Warner, MD, MS, FAMIA, FASCO, and Petros Grivas, MD, Ph.D., join Alicia Morgans, MD, to discuss how the CCC19 consortium has evolved since first being established earlier this...

Predictors of Survival, Healthcare Resource Utilization, and Healthcare Costs in Veterans with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Stephen Freedland

Details
In this discussion, Stephen Freedland, MD, joins Alicia Morgans, MD, MPH, discuss a health economics study that was recently published titled, Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. The objective of this study was to evaluate the association of prostate-specific antigen doubling time (PSADT...

Abiraterone Acetate plus Prednisolone for Hormone-Naïve Prostate Cancer: Long-Term Results from Metastatic (M1) Patients in the STAMPEDE Randomized Trial - Nicholas James

Details
The list of approved and guideline-recommended agents in metastatic hormone-sensitive prostate cancer (mHSPC) has seen significant changes in recent years. At the European Society of Medical Oncology (ESMO) 2020 Virtual Meeting, Dr. Nicholas James presented updated, long-term results of the STAMPEDE Arm G comparison examining abiraterone acetate plus prednisolone in addition to androgen deprivatio...